sting program continu evolv novarti target reduc
quarterli ep may add full year due increas share count
round
novarti leav aduro hand yesterday
close aduro announc novarti decis nv rate remov
portfolio decis base
overal clinic data gener drug associ
safeti concern consequ two on-going trial expect
discontinu phase dose escal trial test
combin novarti spartalizumab
advanc metastat refractori solid tumor lymphoma
enrol expect discontinu patient alreadi studi
set remain treatment progress toxic
phase clinic trial evalu relaps refractori
melanoma combin yervoy ipilimumab note
accord term collabor two compani
progress pivot stage aduro novarti
requir provid fund pivot regardless novarti
opt earli stage addit novarti may honor
reimburs oblig expens relat earli stage
develop acknowledg announc
perceiv overal neg novarti move away
intratumor sting agon note remain commit
target pathway expect pharma
go alter term partnership aduro
phase studi hnscc continu plan
interim data expect note collabor
licens agreement novarti aduro remain effect
importantli earlier stage progress part joint effort continu
develop system deliv sting agonist oncolog
beyond nake journey remain unalt
indic though aduro hand accordingli partner novarti
aduro continu enrol patient phase trial test
combin keytruda patient recurr metastat
head neck squamou cell carcinoma r/r hnscc interim data
expect open-label studi estim enrol
approxim patient project take two year
complet per clinicaltri gov note sinc primari endpoint
orr per recist possibl might receiv earlier look
base compel respons observ also patient might stay
treatment cycl except confirm diseas progress
vesic patient non-muscl invas bladder cancer
expect begin studi fund sole
definit distribut analyst rate analyst certif disclosur pleas refer page report
merck move program forward earli posit first look partner merck rate present
first clinic data asset advanc tumor phase studi signal seek dose
escal studi multipl advanc solid tumor receiv intoler therapi expect confer
benefit individu indic two arm studi monotherapi dose undisclos competit
purpos plu standard dose pembrolizumab keytruda addit upon progress monotherapi arm
patient could crossov combin arm importantli type solid tumor enrol studi expect
respond see respons pembrolizumab breast st cerviv gi hnscc prostat endometri ovarian
studi patient enrol monotherapi arm patient enrol combin arm
patient cross combin arm earli dose escal result highli advanc popul show
one confirm pr monotherapi arm
one confirm pr combin arm
intriguingli crossov arm two patient confirm two confirm pr
pr studi dor six month longer respons occur first assess
merck also enrol expans cohort believ send posit signal investor program
continu move forward import question remain open merck major immunothearpi
combin develop case crossov arm appear perform better arm
end point open end question dose time sequenc well overal kinet immun respons
combin employ
merck partnership remind aduro merck form world-wide licens agreement develop
commerci antibodi agonist agreement initi bionovion up-front
payment million made addit aduro elig receiv mileston payment includ million
develop mileston million commerci sale mileston also note certain research
activ reimburs merck upon approv commerci launch aduro elig receiv royalti
mid-singl digit low teen base net sale product
program expect data health volunt igan patient anti-april antibodi
program intend determin safeti profil compound healthi volunt iga nephropathi igan
patient date administ four healthi volunt dose cohort singl ascend dose portion
one healthi volunt dose cohort multipl ascend dose portion phase clinic trial
treatment iga nephropathi note iga nephropathi new indic aduro pursu preclin data
look encourag abil reduc iga multipl anim model dose depend fashion recal
monoclon antibodi bind bcma/taci receptor b-cell reduc iga igg igm level dose-depend fashion
given mechan action shut antibodi product consid robust preclin data compani
investig hypothes potenti role therapeut strategi abrog auto-antibodi product iga
nephropathi phase clinic trial recent start double-blind placebo-control ascend dose studi
assess safeti profil pk/pd evid mechan action healthi volunt igan patient
per trial design consist three part part double-blind placebo-control singl ascend dose part
double-blind placebo-control multipl ascend dose part igan patient open label multipl dose
valuat risk price target achiev maintain buy rate lower price target
base follow factor adjust base year adjust fulli dilut share count adjust
project reduc project chanc success lower project peak
sale billion broader oncolog indic million hnscc contribut
valuat igan repres valuat merck repres valuat
continu highlight valuat continu exclud earlier stage sting program partnership
rate inflammatori disord oncolog sting program system deliv agonist program
repres potenti upsid valuat target base clinic net present valu npv model model
allow us flex multipl assumpt affect drug potenti commerci profil factor could imped reach
price target includ fail inconclus clinic trial inabl compani secur adequ fund progress
drug develop pathway
million except per share data
licens revenu
product royalti
provis tax
particip prefer stock
net incom common
sec file wainwright estim
ipo april
million except per share data
licens revenu
product royalti
provis tax
particip prefer stock
net incom common
sec file wainwright estim
ipo april
materi confidenti intend use institut account defin finra rule may also
privileg otherwis protect work product immun legal rule receiv mistak pleas let
us know email repli delet system may copi messag
disclos content anyon integr secur messag guarante internet
 wainwright co llc rate wainwright employ three tier rate system evalu
potenti return risk associ own common equiti share rate firm expect return given
equiti measur rel basi compani sector price object calcul estim
potenti movement price given equiti could reach provid certain target met defin time horizon
price object subject extern factor includ industri event market volatil
market outperform buy common stock compani expect outperform passiv index compris
common stock compani within sector
market perform neutral common stock compani expect mimic perform passiv index
compris common stock compani within sector
market under-perform sell common stock compani expect under-perform passiv index compris
common stock compani within sector
rate price target histori inc adro-u
invest bank servic includ limit act manager/co-manag underwrit placement
secur act financi advisor and/or provid corpor financ capit markets-rel servic compani
one affili subsidiari within past month
distribut rate tabl decemb
 wainwright co llc firm member finra sipc regist broker-deal
joseph pantgini ph certifi view express report accur reflect person view
subject secur issuer discuss part compens directli indirectli
relat specif recommend view express research report neither member
household offic director advisori board member compani
none research analyst research analyst household financi interest secur
inc includ without limit option right warrant futur long short posit
novemb neither firm affili benefici class common equiti secur
inc
neither research analyst firm know reason know materi conflict interest time
public research report
research analyst princip respons prepar report receiv compens base upon
specif invest bank servic transact compens base factor includ total revenu profit
firm substanti portion deriv invest bank servic
firm affili receiv compens inc invest bank servic within twelv
month seek compens compani mention report invest bank servic within
three month follow public research report
firm make market inc date research report
secur compani discuss report may unsuit investor depend specif invest
object financi posit past perform guarante futur result report offer inform
purpos constitut offer solicit buy sell secur discuss herein jurisdict
would prohibit research report intend provid tax advic use provid tax advic
person electron version wainwright co llc research report made avail client simultan
part report may reproduc form without express permiss wainwright co llc addit
 wainwright co llc provid individu tailor invest advic research report research report
intend provid person invest advic take account specif invest object financi
situat particular need specif person investor seek financi advic regard appropri
invest financi instrument implement invest strategi discuss recommend research report
 wainwright co llc affili salespeopl trader profession may provid oral written market
commentari trade strategi reflect opinion contrari opinion express research report
 wainwright co llc affili offic director employe exclud analyst time time
long short posit act princip buy sell secur deriv includ option warrant
thereof cover compani refer research report
inform contain herein base sourc believ reliabl guarante us
accur purport complet statement summari avail data compani industri secur
discuss report opinion estim includ report constitut analyst judgment date
report subject chang without notic
secur financi instrument discuss research report may lose valu insur feder
deposit insur corpor subject invest risk includ possibl loss princip amount invest
